Gut & MicrobiomeHow Your Gut Microbiome Controls Whether Cancer Immunotherapy Works
Immune checkpoint blockade (ICB) therapies like anti-PD-1 and anti-CTLA-4 have transformed cancer treatment, but many patients fail to respond. Emerging research shows the gut microbiome may be a critical determinant of who benefits. Specific gut bacteria and the metabolites they produce can either amplify or dampen the immune responses that these therapies depend on. Diet shapes which microbes thrive, creating a chain reaction that reaches far beyond the gut — influencing immune cells attacking tumors in distant organs. This review from Weill Cornell Medicine synthesizes the latest evidence on how diet, gut microbiota, and host immunity interact to influence ICB outcomes, and outlines strategies to harness this axis therapeutically. The implications are significant: modifying the gut microbiome through diet or microbiome-targeted interventions could meaningfully improve cancer immunotherapy response rates.
